The application relates to pyrazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and conditions including fibrosis and liver diseases such as non-alcohol steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
该应用涉及到一般式(I)的
吡唑衍
生物,它们与
溶血磷脂酸受体1(LPAR1)结合并作为LPAR1的拮抗剂。这些化合物可用于治疗包括纤维化和肝病(如非
酒精性脂肪性肝炎(NASH)、间质性肺病(ILD)或慢性肾脏病(CKD))在内的疾病和病状。